BackgroundIn Parkinson's disease (PD), postural instability and gait disorder (PIGD) symptoms are associated with a worse prognosis for an unknown reason.ObjectiveThe objective was to explore the relationship between cannabinoid receptor type 1 (CB1R) availability and motor symptoms in PD with [18F]FMPEP‐d2 positron emission tomography (PET).MethodsFifteen individuals with PD underwent [18F]FMPEP‐d2 PET to measure cerebral CB1R availability. The Unified Parkinson's Disease Rating Scale motor part (UPDRS‐III) was used to evaluate the motor symptoms.ResultsA negative correlation was observed between [18F]FMPEP‐d2 VT and PIGD score (P = 0.002) as well as rigidity subscore (P < 0.001). Both clusters covered widespread areas of both hemispheres. In contrast, tremor or bradykinesia did not correlate to [18F]FMPEP‐d2 VT.ConclusionsGait, postural instability, and rigidity in PD are associated with decreased CB1R availability, unlike tremor or bradykinesia, suggesting that the endocannabinoid system has a role in the pathophysiology of different motor symptoms in PD. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

中文翻译：

---

帕金森病中与 CB1 受体可用性相关的步态受损、姿势不稳和僵硬


背景在帕金森病 （PD） 中，姿势不稳和步态障碍 （PIGD） 症状与预后恶化相关，原因不明。目的目的是通过 [18F]FMPEP-d2 正电子发射断层扫描 （PET） 探讨大麻素受体 1 型 （CB1R） 可用性与 PD 运动症状之间的关系。方法15 例 PD 患者接受 [18F]FMPEP-d2 PET 以测量脑 CB1R 可用性。统一帕金森病评定量表运动部分 （UPDRS-III） 用于评估运动症状。结果观察到 [18F]FMPEP‐d2VT 与 PIGD 评分 （P = 0.002） 以及硬度分评分 （P < 0.001） 之间呈负相关。这两个集群都覆盖了两个半球的广泛区域。相比之下，震颤或运动迟缓与 [18F]FMPEP-d2VT 无关。结论与震颤或运动迟缓不同，PD 的步态、姿势不稳和僵硬与 CB1R 可用性降低有关，这表明内源性大麻素系统在 PD 不同运动症状的病理生理学中发挥作用。© 2024 作者。由 Wiley Periodicals LLC 代表国际帕金森和运动障碍协会出版的《运动障碍》。